Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of ANT3310 + Meropenem in Renal Impairment
NCT06527677Phase 1Completed
- Sponsor
- Antabio
- Start
- Jul 2024
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of pilabactam in bacterial infection, hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP) and 2 more, sponsored by Antabio. Primary endpoints: Maximum Plasma Concentration at Day 3, Area Under the Curve from 0 to infinity at Day 3 and 6 more. Started Jul 2024; status: completed.
02
Drugs
pilabactam
03
Conditions
bacterial infectionhospital-acquired pneumonia (HAP)ventilator-associated pneumonia (VAP)complicated urinary tract infection (cUTI)Intra-abdominal infection (IAI)
Beyond the preview
Go deeper on NCT06527677.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06527677.